cells or neutrophils during their prolonged remission, but a few PNH-affectedlymphocytes were detectable in 3 of 4 patients tested.Laboratory diagnosis can include specialized test, such as sucrosehemolysis test, ham acid hemolysis test and fluorescent-activated cell analysis.Treatment is mainly supportive, consisting of transfusion therapy, anticoagulationtherapy, antibiotic therapy, corticosteroids therapy and supplement therapy whichincludes folic acid and iron. HSCT may be curative. Stress and strenuousactivities are contraindicated to the client. A change and adjustment in lifestyle isencouraged for the client to be able to function in his fullest potential, minimizethe effects of the disease and somehow live a normal life.On March 16, 2007, the U.S. Food and Drug Administration (FDA)approved
(eculizumab) for the treatment of PNH. This medicine works byblocking part of the immune system. It should help decrease the number of bloodtransfusions needed and the number of episodes of blood in the urine.During the year 2008 to 2009, only one case of PNH is recorded at theTarlac Provincial Hospital.
(TPH medical record).
Reason for choosing such case for presentation
Paroxysmal Nocturnal Hemoglubinuria is a rare disease which reallycaptures the group’s interest among the other cases of the confined patients. Itgave a thrill for all of us since we do not have any idea about it and find it verychallenging.The researchers are eager to study about the disease due to lack of information, facts and studies. It is a new exploration. Our curiosity towards thecondition of our patient gave us a lot of questions just like how does the diseaseaffects an individual in different aspects; physically, emotionally, and socially andsomehow to help this client to promote and restore client wellness by providing